MOTS-c
Longevity & Cellular HealthPreclinicalAlso known as: MOTS-c
MOTS-c (Mitochondrial ORF of the Twelve S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide — a member of a recently discovered class of small peptides encoded in mitochondrial DNA rather than nuclear DNA. It was first characterized and named by [Lee et al.
Reconstitution Calculator for MOTS-c
Pre-filled · 5mg vial · 5000mcg dose
Overview
At A Glance
A New Class of Signaling Molecule…
Mechanism of Action
A New Class of Signaling Molecule
MOTS-c belongs to the mitochondrial-derived peptides (MDPs) — a class of small peptides encoded within mitochondrial DNA open reading frames that were historically thought to encode only ribosomal RNAs. The known MDPs include:
- Humanin (24 aa) — neuroprotective, anti-apoptotic
- MOTS-c (16 aa) — metabolic regulation, AMPK activation
- SHLP1-6 (small humanin-like peptides) — various metabolic and neuroprotective effects
This represents a fundamental shift in molecular biology: mitochondria are not just energy factories receiving nuclear instructions, they are themselves endocrine organs producing bioactive peptides that regulate systemic physiology.
AMPK — The Core Mechanism
MOTS-c's primary molecular target is AMP-activated protein kinase (AMPK), a heterotrimeric enzyme that serves as the cellular energy master-regulator. AMPK is activated when intracellular energy status is low (high AMP:ATP ratio) and drives metabolic adaptation:
- Glucose uptake: AMPK activation increases GLUT4 translocation to the muscle cell membrane, independent of insulin. This is the same mechanism underlying exercise-mediated glucose uptake.
- Fatty acid oxidation: AMPK phosphorylates acetyl-CoA carboxylase (ACC), inhibiting malonyl-CoA production and releasing the block on carnitine palmitoyltransferase-1 (CPT1), allowing fatty acids to enter the mitochondrion for β-oxidation.
- Mitochondrial biogenesis: AMPK activates PGC-1α, the master transcriptional coactivator driving mitochondrial biogenesis, improving oxidative capacity.
- Suppression of anabolic pathways: AMPK inhibits mTORC1 (reducing protein synthesis during energy stress), suppresses lipogenesis, and blocks gluconeogenesis.
The net effect is a metabolic shift toward oxidative capacity and glucose disposal — essentially the effects of exercise at the molecular level.
Methionine and Folate Metabolism — The Recent Mechanistic Update
Lee et al., 2015 initially identified MOTS-c as an AMPK activator but the upstream mechanism was unclear. Subsequent work (Lu et al., 2019) identified MOTS-c as a regulator of folate and one-carbon metabolism. Specifically:
- MOTS-c inhibits the folate cycle, reducing cellular methionine synthesis
- Reduced methionine levels produce AMPK activation via AMP elevation
- This places MOTS-c upstream of metformin-like AMPK activation at a specific methionine-cycle node
- Offers mechanistic explanation for MOTS-c's tissue-selective effects
Exercise Mimicry
The parallels between MOTS-c effects and exercise-mediated adaptations are striking:
| Effect | Exercise | MOTS-c |
|---|---|---|
| Muscle glucose uptake | ↑↑ | ↑↑ |
| GLUT4 translocation | ↑↑ | ↑↑ |
| Fatty acid oxidation | ↑↑ | ↑↑ |
| Mitochondrial biogenesis | ↑↑ | ↑↑ |
| Insulin sensitivity | ↑↑ | ↑↑ |
| AMPK phosphorylation | ↑↑ | ↑↑ |
| Endurance capacity | ↑↑ | ↑ (in aged mice) |
This exercise-mimetic profile has generated interest in MOTS-c for populations where exercise is not feasible — frail elderly, disabled, acute-illness recovery — and as an adjunct to exercise for metabolic tuning.
Age-Related Decline
Lee 2015 and subsequent human observational studies document that circulating MOTS-c levels decline progressively with age. In humans, plasma MOTS-c is highest in youth and measurably reduced by the sixth decade. This age-related decline correlates with:
- Decreased insulin sensitivity
- Reduced exercise capacity
- Sarcopenia progression
- Increased visceral adiposity
- Mitochondrial dysfunction at the tissue level
The hypothesis — not yet fully validated — is that MOTS-c decline is causally involved in age-related metabolic deterioration, analogous to the role of declining sex hormones in age-related physical decline. This positions MOTS-c supplementation as a potential longevity intervention distinct from most existing peptide protocols.
Cell-Autonomous and Systemic Effects
MOTS-c operates at two levels:
- Cell-autonomous: Within the cell, mitochondrially-produced MOTS-c acts in an autocrine fashion on AMPK and the folate cycle, influencing local metabolism
- Systemic / endocrine: Circulating MOTS-c reaches distant tissues (muscle, adipose, liver, brain) and drives systemic metabolic effects
This dual action parallels other peptide hormones (insulin acts both locally and systemically) but is unusual for a mitochondrial-derived molecule.
Exercise-Induced Release
Reynolds 2021 and related work demonstrate that exercise itself increases circulating MOTS-c levels in humans, consistent with the idea that MOTS-c is a metabolic stress signal — produced when mitochondria are working hard and needing to broadcast signals about substrate handling. This provides mechanistic explanation for why regular exercise maintains insulin sensitivity and metabolic health: part of the benefit is the MOTS-c signal that exercise generates.
Overview
MOTS-c (Mitochondrial ORF of the Twelve S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide — a member of a recently discovered class of small peptides encoded in mitochondrial DNA rather than nuclear DNA. It was first characterized and named by Lee et al. in 2015 at Pinchas Cohen's laboratory at USC, representing a paradigm shift in mitochondrial biology: the mitochondria are not merely recipients of nuclear regulatory signals, they produce their own signaling peptides that act both locally and systemically on metabolism.
The MOTS-c sequence (M-R-W-Q-E-M-G-Y-I-F-Y-P-R-K-L-R-H) is encoded in the 12S rRNA region of mitochondrial DNA. Under metabolic stress conditions — fasting, caloric restriction, exercise — mitochondria translate and release MOTS-c into circulation, where it acts as an exercise-mimetic and metabolic regulator with primary effects on skeletal muscle, adipose tissue, and liver.
The core pharmacologic mechanism is AMP-activated protein kinase (AMPK) agonism, the same metabolic master-switch targeted by metformin, exercise, and caloric restriction. AMPK activation drives:
- GLUT4 translocation to the muscle cell membrane → increased glucose uptake
- Fatty acid oxidation upregulation via ACC phosphorylation
- Mitochondrial biogenesis via PGC-1α pathway
- Inhibition of de novo lipogenesis and gluconeogenesis
- Improved insulin sensitivity at multiple tissue sites
Preclinical studies document striking effects: MOTS-c treatment in diet-induced obese mice produces weight loss, restored insulin sensitivity, normalized glucose tolerance, and enhanced exercise capacity (Lee 2015; Reynolds 2021). In aging studies, MOTS-c administration to aged mice restores exercise performance to that of young animals and reverses age-related metabolic dysfunction (Reynolds 2021).
Importantly, endogenous MOTS-c levels decline with aging and are suppressed in metabolic disease states. This has generated the hypothesis that declining MDP production is a causal contributor to age-related metabolic decline — positioning MOTS-c replacement as a potential longevity intervention analogous to hormone replacement, though the evidence base is still primarily preclinical.
MOTS-c is not FDA-approved for any indication. Research-chemical use for metabolic tuning, athletic performance, and longevity purposes is emerging but limited; typical protocols use 5-10 mg SC 2-3 times weekly. Human pilot data is scarce; most efficacy inferences come from animal models and mechanistic plausibility.
Potential Research Fields
Chemical Information
IUPAC Name
Mitochondrial open reading frame of 12S rRNA-c (MRFA-peptide)
CAS Number
1600863-63-5
Molecular Formula
C104H181N33O28S
Molecular Mass
2174.39 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
MOTS-c is contraindicated or requires caution in:
Absolute contraindications:
- Pregnancy and lactation — no safety data; avoid
- Pediatric and adolescent use — no pediatric data; developmental effects unknown; not appropriate without specialist supervision
- Active malignancy — complex and unknown effects on tumor cell metabolism; AMPK activation can be anti-cancer or pro-cancer depending on context; avoid until better characterized
- Known hypersensitivity to MOTS-c or the peptide excipients
Strong relative cautions:
- Brittle diabetes or severe hypoglycemia history — AMPK activation enhances glucose uptake; monitor closely if used
- Severe metabolic disease (pheochromocytoma, Addison's disease, severe hypothyroidism) — metabolic homeostasis is fragile; specialist supervision required
- Significant cardiovascular disease — AMPK effects on cardiac metabolism are complex; specialist evaluation before use
- Concurrent metformin at maximal doses — compounded AMPK activation; reduce metformin dose or choose one agent
Relative cautions:
- Active weight loss phase with aggressive caloric restriction — compounding AMPK-activating mechanisms
- Keto or prolonged fasting protocols — similar concern
- Concurrent use of other AMPK activators (berberine, high-dose metformin) — redundant; reconsider need for multiple
- Concurrent sulfonylureas or meglitinides — hypoglycemia risk
- Autoimmune conditions with active flare — AMPK/metabolic shifts may interact with inflammation in unpredictable ways
Drug interactions (monitor):
- Metformin: Redundant AMPK activation; reduce metformin or MOTS-c dose if combining
- Insulin: Additive glucose-lowering; monitor glucose
- Sulfonylureas: Additive hypoglycemic effect
- Rapamycin: Both longevity-oriented; AMPK + mTOR inhibition can significantly reduce muscle protein synthesis; use cautiously
- Anabolic agents (testosterone, IGF-1 LR3, MK-677): AMPK opposes mTOR; combination may blunt anabolic signaling
Theoretical drug interactions (limited data):
- Direct SIRT1 activators (NAD+ precursors, resveratrol, pterostilbene) — complementary mechanism; no contraindication
- Glucocorticoids — likely pharmacodynamic interference but not studied
- Thyroid hormones — metabolic effects may overlap unpredictably
Discontinuation triggers:
- Pregnancy (immediate discontinuation)
- New diagnosis of malignancy (pause until oncology evaluation)
- Persistent severe fatigue beyond 2-3 week adaptation period
- Significant unexpected weight loss without caloric change
- Recurrent hypoglycemic episodes
- Any severe hypersensitivity reaction
- New or worsening symptoms that could plausibly relate to MOTS-c signaling
Given the limited long-term human safety database, a low threshold for discontinuation and re-evaluation is appropriate when any concerns arise.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$38.00
up to $175.00
$2.8750
6
9
vial
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
MOTS-C 10mg | vial | 1 vial● In Stock | $44.99BEST | $4.499 | ||
 |
MOTS-C 10mg | vial | 1 vial● In Stock | $44.99 | $4.499 | ||
 |
MOTS-c 10mg | vial | 1 vial● Out of Stock | $38.00 | $3.800 | — | Sign in for stock alert |
|
|
MOTS-c 40mg | vial | 1 vial● In Stock | $115.00 | $2.875 | — | |
 |
MOTS-C 10mg | vial | 1 vial● In Stock | $44.99 | $4.499 | — | |
|
|
MOTS-C 10mg | vial | 1 vial● In Stock | $54.99 | $5.499 | — | |
 |
MOTS-C 10mg Vial | vial | 1 vial● In Stock | $55.00 | $5.500 | ||
|
|
MOTS-C 40mg Vial | vial | 1 vial● In Stock | $175.00 | $4.375 | ||
 |
MOTS-c 10mg | vial | 10mg vial● In Stock | $59.99 | $5.999 |
Tracking since Mar 13, 2026 · 8 data points
Price History
5 data pointsVendors Selling MOTS-c
Ion Peptide
Optimum Formula
ResearchChemHQ
BioMyst Labs
Nova Peptides
VANDL Labs
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllSide-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for MOTS-c
Research Score
167 PubMed studies
Quality Indicators
Data Completeness
100%COA Verification
10
Verified COAs
2
Vendors w/ COA
High verification rate (83%)
Latest test: 3/1/2026
Research Credibility
Well-researched compound
Quick Facts
Half-Life
~4–6 hours
Molecular Weight
2174.39 g/mol
Administration
Subcutaneous, Intramuscular
CAS Number
1600863-63-5
Trial Phase
Preclinical
Safety Profile
Low RiskCommon Side Effects
- • Mild injection site reactions
- • Transient fatigue (initial doses)
Stop Use If
- Insufficient long-term data — use caution with active diseases
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is MOTS-c and how does it work?
MOTS-c (Mitochondrial ORF of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded in mitochondrial DNA — specifically in the 12S rRNA region. It's one of the mitochondrial-derived peptides (MDPs), a class of signaling molecules discovered relatively recently. MOTS-c activates AMP-activated protein kinase (AMPK), the cellular energy master-switch, producing effects similar to exercise or caloric restriction: increased glucose uptake into muscle, enhanced fatty acid oxidation, mitochondrial biogenesis, improved insulin sensitivity, and suppression of de novo lipogenesis. It was discovered by Pinchas Cohen's lab at USC in 2015 (Lee et al.). Levels decline with age, and animal studies show exogenous MOTS-c can reverse age-related metabolic decline and restore exercise capacity.
What is the best MOTS-c dosage?
Standard protocol is 5-10 mg subcutaneous 2-3 times weekly. Beginners start at 5 mg twice weekly for 8-12 weeks to assess response. Intermediate users run 10 mg 2-3 times weekly. Morning dosing (fasted if possible) aligns with natural AMPK circadian activation. Some athletic users align dosing with hardest training days for synergistic AMPK effect. The single-injection ceiling is approximately 10 mg — beyond this, no additional benefit has been documented. Intermittent dosing (2-3x weekly) is preferred over daily because it mimics the pulsatile release of endogenous MOTS-c during metabolic stress, rather than sustained exposure which may produce different downstream effects.
Does MOTS-c work for weight loss?
Preclinical animal data strongly suggests weight loss effects — MOTS-c produced reduction in visceral adiposity and body weight in diet-induced obese mice without reduced food intake (Lee 2015, Reynolds 2021). Human efficacy data is very limited. The mechanism (AMPK activation, enhanced fatty acid oxidation, improved insulin sensitivity) supports metabolic improvements that would favor fat loss, but the magnitude in humans is unclear. MOTS-c is not a primary weight loss tool the way GLP-1 agonists like semaglutide or tirzepatide are — it works more slowly and subtly, targeting metabolic flexibility rather than appetite suppression. Best positioned as an adjunct to diet and exercise for users seeking metabolic optimization rather than aggressive weight loss.
Can MOTS-c reverse aging?
Preclinical animal data is genuinely striking — MOTS-c administration to aged mice restored exercise capacity, improved mitochondrial function, and reversed age-related metabolic dysfunction (Reynolds 2021 Nat Commun). Human observational data confirms that MOTS-c levels decline with age, and the decline correlates with metabolic deterioration. Whether exogenous MOTS-c replacement produces the same reversal effects in humans is not yet established — no large-scale human longevity trials have been completed. The theoretical mechanism (AMPK activation, mitochondrial biogenesis, metabolic flexibility) aligns with established longevity pathways. MOTS-c is a plausible longevity intervention but the evidence in humans is still preliminary. Users interested in longevity should consider MOTS-c as one component of a broader protocol including exercise, NAD+ support, exercise, and dietary intervention, rather than a standalone solution.
What are the side effects of MOTS-c?
Human side effect data is limited because large-scale clinical trials have not been completed. Reported effects at research doses include mild injection site reactions (most common issue), transient fatigue in the first week as metabolic adaptation occurs, occasional mild headache, and rare nausea. Theoretical concerns include mild hypoglycemia in predisposed users (from AMPK-mediated glucose uptake), reduced muscle protein synthesis during aggressive hypertrophy phases (AMPK/mTOR opposition), and unknown long-term effects on immune function, cognition, and cellular stress response. The limited human database is itself a meaningful consideration — users should understand that MOTS-c is less well-characterized than peptides with larger clinical trial programs.
Can MOTS-c be stacked with NAD+?
Yes — MOTS-c and NAD+ (or NAD+ precursors NMN/NR) are a natural longevity stack. MOTS-c activates AMPK and drives mitochondrial biogenesis; NAD+ fuels sirtuins and mitochondrial respiration. Different mechanisms, same broad target: mitochondrial function and metabolic flexibility. Well-established combination in longevity-focused protocols. Common stack: MOTS-c 10 mg SC 2x weekly + NMN 500-1000 mg oral daily + Urolithin A 500-1000 mg daily for mitophagy. This triple combination targets biogenesis (MOTS-c), sirtuin activation (NAD+), and mitochondrial quality control (Urolithin A). See NAD+ for detailed NAD+ protocols.
Can I use MOTS-c while building muscle?
Theoretically, MOTS-c's AMPK activation opposes mTOR, which is the primary anabolic signaling hub for muscle protein synthesis. This creates theoretical concern that chronic MOTS-c use during aggressive hypertrophy phases could blunt muscle-building. In practice, the effect appears modest, and many users run MOTS-c alongside training without notable muscle loss. That said, during dedicated bulking phases targeting maximum hypertrophy, most experienced practitioners pause MOTS-c and resume it during cutting or maintenance phases where the metabolic benefits are more valuable and the mTOR-suppression is less consequential. For users who train hard but aren't specifically bulking, MOTS-c at standard doses is typically compatible with normal training goals.
Is MOTS-c legal?
MOTS-c is not FDA-approved for any indication in the United States. It is sold through the research-chemical market under research-only classification. Human clinical trial programs are early-stage; no approved therapeutic use exists yet. Users should understand this legal context, source from vendors with third-party purity testing (peptide purity varies significantly across suppliers), and ideally work with a practitioner experienced in peptide therapy. Some 503B compounding pharmacies offer MOTS-c for physician-supervised off-label use, though it's less commonly compounded than well-established peptides like BPC-157 or CJC-1295. See our best vendors guide for reliable research-peptide sources and peptide-friendly clinical practices.
How long does it take MOTS-c to work?
Subjective effects are typically gradual rather than acute. Users may experience mild transient fatigue in the first 1-2 weeks as metabolic adaptation occurs. Energy and exercise tolerance changes may become noticeable at weeks 3-4. Measurable changes in fasting insulin and glucose typically appear at weeks 6-8 in users with baseline metabolic dysfunction. Body composition shifts become detectable at weeks 10-12. Sustained benefits to metabolic flexibility and exercise capacity stabilize by months 4-6 of consistent use. Unlike GLP-1 agonists (rapid appetite suppression and weight loss) or anabolic peptides (fast strength/pump effects), MOTS-c produces gradual metabolic improvements that require consistent use and time to develop fully.
Should I take MOTS-c if I already take metformin?
Both MOTS-c and metformin activate AMPK, though through different upstream mechanisms (MOTS-c via the folate cycle, metformin via complex I inhibition). The combination is not contraindicated but is somewhat redundant. Most practitioners would use one primary AMPK activator at a time rather than stacking for maximum effect. If you're already on metformin for diabetes or off-label longevity purposes and considering MOTS-c, reasonable approaches are: (1) continue metformin at reduced dose while adding MOTS-c, (2) take MOTS-c in place of metformin if your clinical situation allows (specialist discussion required), or (3) continue metformin and add MOTS-c with careful glucose monitoring — the combined AMPK activation could produce more pronounced glucose-lowering than either alone. Discuss with a physician experienced in metabolic pharmacology before combining.
Research Tools
Related Compounds
View AllSide-by-Side Comparisons
All ComparisonsCompare MOTS-c head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.